Global Atopic Dermatitis Treatment

Atopic Dermatitis Treatment Comprehensive Study by Route of Administration (Oral, Topical, Injectable), Treatment (Medications, Wet Dressings, Light Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Drug Class (Corticosteroids, Anti-histamines, Calcineurin inhibitors, Interleukin inhibitors, Topical phosphodiesterase-4, Antibiotics, Others) Players and Region - Global Market Outlook to 2030

Atopic Dermatitis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Atopic Dermatitis Treatment
Atopic dermatitis, also known as eczema, is a common allergic skin disease that makes skin red and itchy usually starts in early childhood. This skin disease can be associated with infection of bacteria, fungi, yeast and viruses. This condition is common in children but can occur at any age. Half of the patients suffering from moderate to severe atopic dermatitis also suffer from asthma, hay fever (allergic rhinitis), and food allergies. No cure has been found for this condition, but treatment and self-care measures can relieve itching and prevent new outbreaks.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Atopic Dermatitis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi S.A. (France), Allergan, Inc. (Ireland), Novartis International AG (Switzerland), Bristol Myers Squibb (United States), Bayer AG (Germany), Meda Pharmaceuticals (Sweden), Anacor Pharmaceutical (United States), Pfizer Inc. (United States), Astellas Pharma Inc. (Japan) and Regeneron Pharmaceuticals, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Atopic Dermatitis Treatment market by and Region.



On the basis of geography, the market of Atopic Dermatitis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Medications will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Corticosteroids will boost the Atopic Dermatitis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Research and Development Activities and Improving Healthcare Facilities

Market Growth Drivers:
Rising Awareness among People about Treatment Options available for Atopic Dermatitis and Increasing Prevalence of Atopic Dermatitis among Children

Challenges:
Stringent Government Rules and Regulations

Restraints:
High Cost of Therapeutics

Opportunities:
Growth in the Healthcare Industry Worldwide and Increasing Government Fundings for Affordable Treatments

Market Leaders and their expansionary development strategies
On October 26, 2023, Regeneron and Sanofi announced a collaboration to develop and commercialize REGN4210, a novel investigational interleukin-23 (IL-23) receptor antibody, for the treatment of various inflammatory diseases, including moderate-to-severe atopic dermatitis.
On September 19, 2023, LEO Pharma and Almirall entered into a strategic partnership to co-commercialize LEO Pharma's JAK1 inhibitor, LEO 10367, for the treatment of atopic dermatitis and other immune-mediated diseases.


Key Target Audience
Atopic Dermatitis Treatment Providers, Emerging Companies, Research Professionals, Distributors and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Route of Administration
  • Oral
  • Topical
  • Injectable

By Treatment
  • Medications
  • Wet Dressings
  • Light Therapy
  • Others

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Drug Class
  • Corticosteroids
  • Anti-histamines
  • Calcineurin inhibitors
  • Interleukin inhibitors
  • Topical phosphodiesterase-4
  • Antibiotics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness among People about Treatment Options available for Atopic Dermatitis
      • 3.2.2. Increasing Prevalence of Atopic Dermatitis among Children
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Improving Healthcare Facilities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Atopic Dermatitis Treatment, by Route of Administration, Treatment, Distribution Channel, Drug Class and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Atopic Dermatitis Treatment (Value)
      • 5.2.1. Global Atopic Dermatitis Treatment by: Route of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Topical
        • 5.2.1.3. Injectable
      • 5.2.2. Global Atopic Dermatitis Treatment by: Treatment (Value)
        • 5.2.2.1. Medications
        • 5.2.2.2. Wet Dressings
        • 5.2.2.3. Light Therapy
        • 5.2.2.4. Others
      • 5.2.3. Global Atopic Dermatitis Treatment by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Atopic Dermatitis Treatment by: Drug Class (Value)
        • 5.2.4.1. Corticosteroids
        • 5.2.4.2. Anti-histamines
        • 5.2.4.3. Calcineurin inhibitors
        • 5.2.4.4. Interleukin inhibitors
        • 5.2.4.5. Topical phosphodiesterase-4
        • 5.2.4.6. Antibiotics
        • 5.2.4.7. Others
      • 5.2.5. Global Atopic Dermatitis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Atopic Dermatitis Treatment (Price)
  • 6. Atopic Dermatitis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A. (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan, Inc. (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol Myers Squibb (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Meda Pharmaceuticals (Sweden)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Anacor Pharmaceutical (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Astellas Pharma Inc. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Atopic Dermatitis Treatment Sale, by Route of Administration, Treatment, Distribution Channel, Drug Class and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Atopic Dermatitis Treatment (Value)
      • 7.2.1. Global Atopic Dermatitis Treatment by: Route of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Topical
        • 7.2.1.3. Injectable
      • 7.2.2. Global Atopic Dermatitis Treatment by: Treatment (Value)
        • 7.2.2.1. Medications
        • 7.2.2.2. Wet Dressings
        • 7.2.2.3. Light Therapy
        • 7.2.2.4. Others
      • 7.2.3. Global Atopic Dermatitis Treatment by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Atopic Dermatitis Treatment by: Drug Class (Value)
        • 7.2.4.1. Corticosteroids
        • 7.2.4.2. Anti-histamines
        • 7.2.4.3. Calcineurin inhibitors
        • 7.2.4.4. Interleukin inhibitors
        • 7.2.4.5. Topical phosphodiesterase-4
        • 7.2.4.6. Antibiotics
        • 7.2.4.7. Others
      • 7.2.5. Global Atopic Dermatitis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Atopic Dermatitis Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Atopic Dermatitis Treatment: by Route of Administration(USD Million)
  • Table 2. Atopic Dermatitis Treatment Oral , by Region USD Million (2018-2023)
  • Table 3. Atopic Dermatitis Treatment Topical , by Region USD Million (2018-2023)
  • Table 4. Atopic Dermatitis Treatment Injectable , by Region USD Million (2018-2023)
  • Table 5. Atopic Dermatitis Treatment: by Treatment(USD Million)
  • Table 6. Atopic Dermatitis Treatment Medications , by Region USD Million (2018-2023)
  • Table 7. Atopic Dermatitis Treatment Wet Dressings , by Region USD Million (2018-2023)
  • Table 8. Atopic Dermatitis Treatment Light Therapy , by Region USD Million (2018-2023)
  • Table 9. Atopic Dermatitis Treatment Others , by Region USD Million (2018-2023)
  • Table 10. Atopic Dermatitis Treatment: by Distribution Channel(USD Million)
  • Table 11. Atopic Dermatitis Treatment Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Atopic Dermatitis Treatment Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Atopic Dermatitis Treatment Online Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Atopic Dermatitis Treatment: by Drug Class(USD Million)
  • Table 15. Atopic Dermatitis Treatment Corticosteroids , by Region USD Million (2018-2023)
  • Table 16. Atopic Dermatitis Treatment Anti-histamines , by Region USD Million (2018-2023)
  • Table 17. Atopic Dermatitis Treatment Calcineurin inhibitors , by Region USD Million (2018-2023)
  • Table 18. Atopic Dermatitis Treatment Interleukin inhibitors , by Region USD Million (2018-2023)
  • Table 19. Atopic Dermatitis Treatment Topical phosphodiesterase-4 , by Region USD Million (2018-2023)
  • Table 20. Atopic Dermatitis Treatment Antibiotics , by Region USD Million (2018-2023)
  • Table 21. Atopic Dermatitis Treatment Others , by Region USD Million (2018-2023)
  • Table 22. South America Atopic Dermatitis Treatment, by Country USD Million (2018-2023)
  • Table 23. South America Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 24. South America Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 25. South America Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 26. South America Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 27. Brazil Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 28. Brazil Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 29. Brazil Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 30. Brazil Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 31. Argentina Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 32. Argentina Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 33. Argentina Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 34. Argentina Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 35. Rest of South America Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 36. Rest of South America Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 37. Rest of South America Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 38. Rest of South America Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 39. Asia Pacific Atopic Dermatitis Treatment, by Country USD Million (2018-2023)
  • Table 40. Asia Pacific Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 41. Asia Pacific Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 42. Asia Pacific Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 43. Asia Pacific Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 44. China Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 45. China Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 46. China Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 47. China Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 48. Japan Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 49. Japan Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 50. Japan Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 51. Japan Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 52. India Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 53. India Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 54. India Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 55. India Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 56. South Korea Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 57. South Korea Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 58. South Korea Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 59. South Korea Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 60. Taiwan Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 61. Taiwan Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 62. Taiwan Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 63. Taiwan Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 64. Australia Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 65. Australia Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 66. Australia Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 67. Australia Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 71. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 72. Europe Atopic Dermatitis Treatment, by Country USD Million (2018-2023)
  • Table 73. Europe Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 74. Europe Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 75. Europe Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 76. Europe Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 77. Germany Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 78. Germany Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 79. Germany Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 80. Germany Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 81. France Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 82. France Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 83. France Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 84. France Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 85. Italy Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 86. Italy Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 87. Italy Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 88. Italy Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 89. United Kingdom Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 90. United Kingdom Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 91. United Kingdom Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 92. United Kingdom Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 93. Netherlands Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 94. Netherlands Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 95. Netherlands Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 96. Netherlands Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 97. Rest of Europe Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 98. Rest of Europe Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 99. Rest of Europe Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 100. Rest of Europe Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 101. MEA Atopic Dermatitis Treatment, by Country USD Million (2018-2023)
  • Table 102. MEA Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 103. MEA Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 104. MEA Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 105. MEA Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 106. Middle East Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 107. Middle East Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 108. Middle East Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 109. Middle East Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 110. Africa Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 111. Africa Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 112. Africa Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 113. Africa Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 114. North America Atopic Dermatitis Treatment, by Country USD Million (2018-2023)
  • Table 115. North America Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 116. North America Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 117. North America Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 118. North America Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 119. United States Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 120. United States Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 121. United States Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 122. United States Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 123. Canada Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 124. Canada Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 125. Canada Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 126. Canada Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 127. Mexico Atopic Dermatitis Treatment, by Route of Administration USD Million (2018-2023)
  • Table 128. Mexico Atopic Dermatitis Treatment, by Treatment USD Million (2018-2023)
  • Table 129. Mexico Atopic Dermatitis Treatment, by Distribution Channel USD Million (2018-2023)
  • Table 130. Mexico Atopic Dermatitis Treatment, by Drug Class USD Million (2018-2023)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Atopic Dermatitis Treatment: by Route of Administration(USD Million)
  • Table 142. Atopic Dermatitis Treatment Oral , by Region USD Million (2025-2030)
  • Table 143. Atopic Dermatitis Treatment Topical , by Region USD Million (2025-2030)
  • Table 144. Atopic Dermatitis Treatment Injectable , by Region USD Million (2025-2030)
  • Table 145. Atopic Dermatitis Treatment: by Treatment(USD Million)
  • Table 146. Atopic Dermatitis Treatment Medications , by Region USD Million (2025-2030)
  • Table 147. Atopic Dermatitis Treatment Wet Dressings , by Region USD Million (2025-2030)
  • Table 148. Atopic Dermatitis Treatment Light Therapy , by Region USD Million (2025-2030)
  • Table 149. Atopic Dermatitis Treatment Others , by Region USD Million (2025-2030)
  • Table 150. Atopic Dermatitis Treatment: by Distribution Channel(USD Million)
  • Table 151. Atopic Dermatitis Treatment Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 152. Atopic Dermatitis Treatment Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 153. Atopic Dermatitis Treatment Online Pharmacies , by Region USD Million (2025-2030)
  • Table 154. Atopic Dermatitis Treatment: by Drug Class(USD Million)
  • Table 155. Atopic Dermatitis Treatment Corticosteroids , by Region USD Million (2025-2030)
  • Table 156. Atopic Dermatitis Treatment Anti-histamines , by Region USD Million (2025-2030)
  • Table 157. Atopic Dermatitis Treatment Calcineurin inhibitors , by Region USD Million (2025-2030)
  • Table 158. Atopic Dermatitis Treatment Interleukin inhibitors , by Region USD Million (2025-2030)
  • Table 159. Atopic Dermatitis Treatment Topical phosphodiesterase-4 , by Region USD Million (2025-2030)
  • Table 160. Atopic Dermatitis Treatment Antibiotics , by Region USD Million (2025-2030)
  • Table 161. Atopic Dermatitis Treatment Others , by Region USD Million (2025-2030)
  • Table 162. South America Atopic Dermatitis Treatment, by Country USD Million (2025-2030)
  • Table 163. South America Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 164. South America Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 165. South America Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 166. South America Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 167. Brazil Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 168. Brazil Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 169. Brazil Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 170. Brazil Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 171. Argentina Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 172. Argentina Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 173. Argentina Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 174. Argentina Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 175. Rest of South America Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 176. Rest of South America Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 177. Rest of South America Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 178. Rest of South America Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 179. Asia Pacific Atopic Dermatitis Treatment, by Country USD Million (2025-2030)
  • Table 180. Asia Pacific Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 181. Asia Pacific Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 182. Asia Pacific Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 183. Asia Pacific Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 184. China Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 185. China Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 186. China Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 187. China Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 188. Japan Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 189. Japan Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 190. Japan Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 191. Japan Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 192. India Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 193. India Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 194. India Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 195. India Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 196. South Korea Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 197. South Korea Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 198. South Korea Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 199. South Korea Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 200. Taiwan Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 201. Taiwan Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 202. Taiwan Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 203. Taiwan Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 204. Australia Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 205. Australia Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 206. Australia Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 207. Australia Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 210. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 211. Rest of Asia-Pacific Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 212. Europe Atopic Dermatitis Treatment, by Country USD Million (2025-2030)
  • Table 213. Europe Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 214. Europe Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 215. Europe Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 216. Europe Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 217. Germany Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 218. Germany Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 219. Germany Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 220. Germany Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 221. France Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 222. France Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 223. France Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 224. France Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 225. Italy Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 226. Italy Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 227. Italy Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 228. Italy Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 229. United Kingdom Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 230. United Kingdom Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 231. United Kingdom Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 232. United Kingdom Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 233. Netherlands Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 234. Netherlands Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 235. Netherlands Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 236. Netherlands Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 237. Rest of Europe Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 238. Rest of Europe Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 239. Rest of Europe Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 240. Rest of Europe Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 241. MEA Atopic Dermatitis Treatment, by Country USD Million (2025-2030)
  • Table 242. MEA Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 243. MEA Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 244. MEA Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 245. MEA Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 246. Middle East Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 247. Middle East Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 248. Middle East Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 249. Middle East Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 250. Africa Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 251. Africa Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 252. Africa Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 253. Africa Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 254. North America Atopic Dermatitis Treatment, by Country USD Million (2025-2030)
  • Table 255. North America Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 256. North America Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 257. North America Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 258. North America Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 259. United States Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 260. United States Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 261. United States Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 262. United States Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 263. Canada Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 264. Canada Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 265. Canada Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 266. Canada Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 267. Mexico Atopic Dermatitis Treatment, by Route of Administration USD Million (2025-2030)
  • Table 268. Mexico Atopic Dermatitis Treatment, by Treatment USD Million (2025-2030)
  • Table 269. Mexico Atopic Dermatitis Treatment, by Distribution Channel USD Million (2025-2030)
  • Table 270. Mexico Atopic Dermatitis Treatment, by Drug Class USD Million (2025-2030)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Atopic Dermatitis Treatment: by Route of Administration USD Million (2018-2023)
  • Figure 5. Global Atopic Dermatitis Treatment: by Treatment USD Million (2018-2023)
  • Figure 6. Global Atopic Dermatitis Treatment: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Atopic Dermatitis Treatment: by Drug Class USD Million (2018-2023)
  • Figure 8. South America Atopic Dermatitis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Atopic Dermatitis Treatment Share (%), by Country
  • Figure 10. Europe Atopic Dermatitis Treatment Share (%), by Country
  • Figure 11. MEA Atopic Dermatitis Treatment Share (%), by Country
  • Figure 12. North America Atopic Dermatitis Treatment Share (%), by Country
  • Figure 13. Global Atopic Dermatitis Treatment share by Players 2023 (%)
  • Figure 14. Global Atopic Dermatitis Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Atopic Dermatitis Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 19. Allergan, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Allergan, Inc. (Ireland) Revenue: by Geography 2023
  • Figure 21. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 27. Meda Pharmaceuticals (Sweden) Revenue, Net Income and Gross profit
  • Figure 28. Meda Pharmaceuticals (Sweden) Revenue: by Geography 2023
  • Figure 29. Anacor Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 30. Anacor Pharmaceutical (United States) Revenue: by Geography 2023
  • Figure 31. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 35. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 37. Global Atopic Dermatitis Treatment: by Route of Administration USD Million (2025-2030)
  • Figure 38. Global Atopic Dermatitis Treatment: by Treatment USD Million (2025-2030)
  • Figure 39. Global Atopic Dermatitis Treatment: by Distribution Channel USD Million (2025-2030)
  • Figure 40. Global Atopic Dermatitis Treatment: by Drug Class USD Million (2025-2030)
  • Figure 41. South America Atopic Dermatitis Treatment Share (%), by Country
  • Figure 42. Asia Pacific Atopic Dermatitis Treatment Share (%), by Country
  • Figure 43. Europe Atopic Dermatitis Treatment Share (%), by Country
  • Figure 44. MEA Atopic Dermatitis Treatment Share (%), by Country
  • Figure 45. North America Atopic Dermatitis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi S.A. (France)
  • Allergan, Inc. (Ireland)
  • Novartis International AG (Switzerland)
  • Bristol Myers Squibb (United States)
  • Bayer AG (Germany)
  • Meda Pharmaceuticals (Sweden)
  • Anacor Pharmaceutical (United States)
  • Pfizer Inc. (United States)
  • Astellas Pharma Inc. (Japan)
  • Regeneron Pharmaceuticals, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 243 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Atopic Dermatitis Treatment Quantitative research analysis
Global Atopic Dermatitis Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi S.A. (France), Allergan, Inc. (Ireland), Novartis International AG (Switzerland), Bristol Myers Squibb (United States), Bayer AG (Germany), Meda Pharmaceuticals (Sweden), Anacor Pharmaceutical (United States), Pfizer Inc. (United States), Astellas Pharma Inc. (Japan) and Regeneron Pharmaceuticals, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Research and Development Activities " is seen as one of major influencing trends for Atopic Dermatitis Treatment Market during projected period 2023-2030.
The Atopic Dermatitis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Atopic Dermatitis Treatment Report?

Have a Query? Click Here

Other Related Reports

Axial Spondyloarthritis Treatment Comprehensive Study by Type (COX-2 Antagonists, COX Inhibitors, Others), Application (Hospital, Rehabilitation Center, Other), Distribution Channel (Online, Medical ...
$ 3650
Carotid Endarterectomy Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centre, Others), Diagnosis (Computed Tomography Angiography, Carotid Ultrasound, Magnetic Resonance ...
$ 3500
Wilson's Disease Treatment Comprehensive Study by Type (Medication (Trientine, Penicillamine, Zinc Acatate), Surgery), Application (Hospitals, Specialty Clinics, Diagnostic Laboratories), Test Type (...
$ 3750
Myelodysplastic Syndrome Comprehensive Study by Type (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors, Others), Application (Hospital, Clinic), Route of Administration (Generic, Or...
$ 3650
Vertebral Compression Fracture Devices Comprehensive Study by Type (Balloon Kyphoplasty Devices, Vertebroplasty Devices), Surgery Type (Open Spine Surgery, Minimally Invasive Spine Surgery, Lumbar Fu...
$ 3650
Chronic Obstructive Pulmonary Disease Comprehensive Study by Disease Type (Emphysema, Chronic Bronchitis), Age Group (Children, Adults), Treatment Type (Medication, Oxygen Therapy, Pulmonary Rehabili...
$ 3800